These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 32797801)

  • 21. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.
    Evans BW; Clark WK; Moore DJ; Whorwell PJ
    Cochrane Database Syst Rev; 2007 Oct; (4):CD003960. PubMed ID: 17943807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome.
    Prather CM; Camilleri M; Zinsmeister AR; McKinzie S; Thomforde G
    Gastroenterology; 2000 Mar; 118(3):463-8. PubMed ID: 10702196
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review article: tegaserod.
    Camilleri M
    Aliment Pharmacol Ther; 2001 Mar; 15(3):277-89. PubMed ID: 11207504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cisapride in neurologically impaired children with chronic constipation.
    Staiano A; Del Giudice E; Simeone D; Miele E; Marino A
    Dig Dis Sci; 1996 May; 41(5):870-4. PubMed ID: 8625757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased cholinergic contractions of jejunal smooth muscle caused by a high cholesterol diet are prevented by the 5-HT4 agonist--tegaserod.
    Mathison R; Shaffer E
    BMC Gastroenterol; 2006 Feb; 6():8. PubMed ID: 16504074
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders.
    Wiseman LR; Faulds D
    Drugs; 1994 Jan; 47(1):116-52. PubMed ID: 7510617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effects of various prokinetic drugs on gastrointestinal transit times in patients with progressive systemic scleroderma].
    Folwaczny C; Läritz M; Meurer M; Endres SP; König A; Schindlbeck N
    Z Gastroenterol; 1997 Oct; 35(10):905-12. PubMed ID: 9432812
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of cisapride on chronic idiopathic constipation in children.
    Staiano A; Cucchiara S; Andreotti MR; Minella R; Manzi G
    Dig Dis Sci; 1991 Jun; 36(6):733-6. PubMed ID: 2032513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mangiferin, a natural xanthone, accelerates gastrointestinal transit in mice involving cholinergic mechanism.
    Cavalcante Morais T; Cavalcante Lopes S; Bezerra Carvalho KM; Rodrigues Arruda B; Correia de Souza FT; Salles Trevisan MT; Rao VS; Almeida Santos F
    World J Gastroenterol; 2012 Jul; 18(25):3207-14. PubMed ID: 22783044
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of tegaserod in chronic constipation in men.
    Fried M; Johanson JF; Gwee KA; Wagner A; Pecher E; Rueegg P
    Am J Gastroenterol; 2007 Feb; 102(2):362-70. PubMed ID: 17156137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prokinetic effect of cisapride on pedicled stomach, small bowel and colon grafts replacing the esophagus after esophageal resection.
    Kalmár K; Vereczkei ; Zámbó K; Pótó L; Horváth OP
    Dis Esophagus; 2003; 16(4):291-4. PubMed ID: 14641291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of Cisapride, Buprenorphine, and Their Combination on Gastrointestinal Transit in New Zealand White Rabbits.
    Feldman ER; Singh B; Mishkin NG; Lachenauer ER; Martin-Flores M; Daugherity EK
    J Am Assoc Lab Anim Sci; 2021 Mar; 60(2):221-228. PubMed ID: 33632373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of tegaserod and erythromycin in upper gut dysmotility: a comparative study.
    Nasr I; Rao SS; Attaluri A; Hashmi SM; Summers R
    Indian J Gastroenterol; 2009; 28(4):136-42. PubMed ID: 19937173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of mosapride citrate, metoclopramide hydrochloride, lidocaine hydrochloride, and cisapride citrate on equine gastric emptying, small intestinal and caecal motility.
    Okamura K; Sasaki N; Yamada M; Yamada H; Inokuma H
    Res Vet Sci; 2009 Apr; 86(2):302-8. PubMed ID: 18723200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tegaserod for the treatment of irritable bowel syndrome.
    Evans BW; Clark WK; Moore DJ; Whorwell PJ
    Cochrane Database Syst Rev; 2004; (1):CD003960. PubMed ID: 14974049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cisapride for the treatment of constipation in children: A double-blind study.
    Nurko S; Garcia-Aranda JA; Worona LB; Zlochisty O
    J Pediatr; 2000 Jan; 136(1):35-40. PubMed ID: 10636971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and tolerability of tegaserod in irritable bowel syndrome management.
    Berardi RR
    J Am Pharm Assoc (2003); 2004; 44(1):41-51. PubMed ID: 14965152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of cisapride on gall bladder emptying, intestinal transit, and serum deoxycholate: a prospective, randomised, double blind, placebo controlled trial.
    Veysey MJ; Malcolm P; Mallet AI; Jenkins PJ; Besser GM; Murphy GM; Dowling RH
    Gut; 2001 Dec; 49(6):828-34. PubMed ID: 11709518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relative efficacy of some prokinetic drugs in morphine-induced gastrointestinal transit delay in mice.
    Suchitra AD; Dkhar SA; Shewade DG; Shashindran CH
    World J Gastroenterol; 2003 Apr; 9(4):779-83. PubMed ID: 12679931
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.
    Harish K; Hazeena K; Thomas V; Kumar S; Jose T; Narayanan P
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1183-9. PubMed ID: 17688659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.